Pharmaceutics Exam 1 and 2 || || || || ||
questions with answers || || ||
Each item below contains three suggested answers of
|| || || || || || || ||
which one or more is correct. Healthy human volunteers
|| || || || || || || || ||
are used in drug development for
|| || || || ||
I. Phase I testing after the submission of an investigated
|| || || || || || || || || ||
new drug (IND) application
|| || ||
II. phase II clinical testing phase
|| || || || ||
III. testing just before the submission of a new drug
|| || || || || || || || || ||
application (NDA). ||
A. If I only is correct
|| || || || ||
B. If II only is correct
|| || || || ||
C. If III only is correct
|| || || || ||
D. If I and II are correct
|| || || || || ||
E. If II and III are correct
|| || || || || ||
F. If I, II, and III are correct - CORRECT
|| || || || || || || || || ||
ANSWER(S)✔✔A. If I only is correct || || || || ||
Each item below contains three suggested answers of
|| || || || || || || ||
which one or more is correct || || || || ||
,The required information contained in a new drug
|| || || || || || || ||
application (NDA) that is not included in the abbreviated || || || || || || || || ||
new drug application (ANDA)
|| || ||
I. preclinical animal toxicity studies
|| || || ||
II. clinical efficacy studies
|| || ||
III. bioavailability and bioequivalence studies
|| || || ||
A. If I only is correct
|| || || || ||
B. If II only is correct
|| || || || ||
C. If III only is correct
|| || || || ||
D. If I and II are correct
|| || || || || ||
E. If II and III are correct
|| || || || || ||
F. If I, II, and III are correct - CORRECT
|| || || || || || || || || ||
ANSWER(S)✔✔D. If I and II are correct || || || || || ||
True or False. Bioavailability is lowest for those drugs
|| || || || || || || || ||
that undergo a significant first-pass effect. - CORRECT
|| || || || || || || ||
ANSWER(S)✔✔True
All the following properties make plastics suitable as
|| || || || || || || ||
packaging materials for pharmaceutical dosage forms || || || || || ||
EXCEPT
,A. light in weight
|| || ||
B. Low cost of transportation
|| || || ||
C. sorption of drugs
|| || ||
D. reproducibility of plastic synthesis - CORRECT
|| || || || || || ||
ANSWER(S)✔✔C. sorption of drugs || || ||
Which equation is used to predict the influence of
|| || || || || || || || ||
particle size on drug dissolution rate?
|| || || || || ||
A. The Stokes equation
|| || ||
B. theArrhenius equation
|| ||
C. the Noyes Whitney equation
|| || || ||
D. Henderson-Hasselbalch equation - CORRECT
|| || || || ||
ANSWER(S)✔✔C. the Noyes Whitney equation || || || ||
The 2005 USP(28)/ NF(23) include the following
|| || || || || ||
A. Detailed monographs on drug substances
|| || || || ||
B. Detailed monographs on dosage forms
|| || || || ||
C. detailed monographs on pharmaceutical ingredients
|| || || || || ||
or excipients
||
D. A,B, & C are wrong
|| || || || ||
, E. A,B, & C are correct - CORRECT ANSWER(S)✔✔E.
|| || || || || || || || ||
A,B, & C are correct
|| || || ||
It is believed that bioavailability is lowest for those drugs
|| || || || || || || || ||
that undergo a significant first-pass effect, when
|| || || || || || || ||
administered orally. Other route(s) of drug || || || || || ||
administration that a formulation pharmacist may || || || || || ||
consider include ||
A. Intravenous route
|| ||
B. Intramuscular route
|| ||
C. Sublingual route
|| ||
D. A,B, & C are wrong
|| || || || ||
E. A,B, & C are correct - CORRECT ANSWER(S)✔✔E.
|| || || || || || || || ||
A,B, & C are correct
|| || || ||
The disadvantages of the oral route of drug
|| || || || || || || ||
administration include the following except || || || || ||
A. Slow drug response
|| || ||
B. slow onset of action
|| || || ||
C. erratic drug absorption
|| || ||
D. Lack of destruction of certain drugs by the acid or by
|| || || || || || || || || || || ||
gastrointestinal enzymes. - CORRECT ANSWER(S)✔✔D. || || || || ||
questions with answers || || ||
Each item below contains three suggested answers of
|| || || || || || || ||
which one or more is correct. Healthy human volunteers
|| || || || || || || || ||
are used in drug development for
|| || || || ||
I. Phase I testing after the submission of an investigated
|| || || || || || || || || ||
new drug (IND) application
|| || ||
II. phase II clinical testing phase
|| || || || ||
III. testing just before the submission of a new drug
|| || || || || || || || || ||
application (NDA). ||
A. If I only is correct
|| || || || ||
B. If II only is correct
|| || || || ||
C. If III only is correct
|| || || || ||
D. If I and II are correct
|| || || || || ||
E. If II and III are correct
|| || || || || ||
F. If I, II, and III are correct - CORRECT
|| || || || || || || || || ||
ANSWER(S)✔✔A. If I only is correct || || || || ||
Each item below contains three suggested answers of
|| || || || || || || ||
which one or more is correct || || || || ||
,The required information contained in a new drug
|| || || || || || || ||
application (NDA) that is not included in the abbreviated || || || || || || || || ||
new drug application (ANDA)
|| || ||
I. preclinical animal toxicity studies
|| || || ||
II. clinical efficacy studies
|| || ||
III. bioavailability and bioequivalence studies
|| || || ||
A. If I only is correct
|| || || || ||
B. If II only is correct
|| || || || ||
C. If III only is correct
|| || || || ||
D. If I and II are correct
|| || || || || ||
E. If II and III are correct
|| || || || || ||
F. If I, II, and III are correct - CORRECT
|| || || || || || || || || ||
ANSWER(S)✔✔D. If I and II are correct || || || || || ||
True or False. Bioavailability is lowest for those drugs
|| || || || || || || || ||
that undergo a significant first-pass effect. - CORRECT
|| || || || || || || ||
ANSWER(S)✔✔True
All the following properties make plastics suitable as
|| || || || || || || ||
packaging materials for pharmaceutical dosage forms || || || || || ||
EXCEPT
,A. light in weight
|| || ||
B. Low cost of transportation
|| || || ||
C. sorption of drugs
|| || ||
D. reproducibility of plastic synthesis - CORRECT
|| || || || || || ||
ANSWER(S)✔✔C. sorption of drugs || || ||
Which equation is used to predict the influence of
|| || || || || || || || ||
particle size on drug dissolution rate?
|| || || || || ||
A. The Stokes equation
|| || ||
B. theArrhenius equation
|| ||
C. the Noyes Whitney equation
|| || || ||
D. Henderson-Hasselbalch equation - CORRECT
|| || || || ||
ANSWER(S)✔✔C. the Noyes Whitney equation || || || ||
The 2005 USP(28)/ NF(23) include the following
|| || || || || ||
A. Detailed monographs on drug substances
|| || || || ||
B. Detailed monographs on dosage forms
|| || || || ||
C. detailed monographs on pharmaceutical ingredients
|| || || || || ||
or excipients
||
D. A,B, & C are wrong
|| || || || ||
, E. A,B, & C are correct - CORRECT ANSWER(S)✔✔E.
|| || || || || || || || ||
A,B, & C are correct
|| || || ||
It is believed that bioavailability is lowest for those drugs
|| || || || || || || || ||
that undergo a significant first-pass effect, when
|| || || || || || || ||
administered orally. Other route(s) of drug || || || || || ||
administration that a formulation pharmacist may || || || || || ||
consider include ||
A. Intravenous route
|| ||
B. Intramuscular route
|| ||
C. Sublingual route
|| ||
D. A,B, & C are wrong
|| || || || ||
E. A,B, & C are correct - CORRECT ANSWER(S)✔✔E.
|| || || || || || || || ||
A,B, & C are correct
|| || || ||
The disadvantages of the oral route of drug
|| || || || || || || ||
administration include the following except || || || || ||
A. Slow drug response
|| || ||
B. slow onset of action
|| || || ||
C. erratic drug absorption
|| || ||
D. Lack of destruction of certain drugs by the acid or by
|| || || || || || || || || || || ||
gastrointestinal enzymes. - CORRECT ANSWER(S)✔✔D. || || || || ||
